News – Page 985 – Endpoints News

FDA revises draft guidance on rare disease drug R&D

7 years ago

AstraZeneca signs deal to promote product made in China — in mainland China; Israeli deep brain stimulation co ...

7 years ago

Dragonfly preps clinical takeoff, inking a collaboration pact with MD Anderson

7 years ago

Aptinyx shares crater as lead drug fails in PhII neuropathic pain study

7 years ago

Allergan and its Mohawk allies pitch their sovereign immunity case to SCOTUS. And the timing couldn't be worse

7 years ago

Blocking PD-L1 production in mice, UCSF team spotlights preclinical promise of a Pfizer-backed I/O drug

7 years ago

Live to 150? Jim Mellon and the crew at Juvenescence just raised $46M more to give it a try

7 years ago

Five Prime cuts 41 jobs, days before presenting data at ASCO meeting of GI cancers

7 years ago

Gottlieb, Marks detail plans to advance development of cell and gene therapies

7 years ago

Harvard prof David Sinclair backs anti-aging upstart Life Bio, which just raised $50M for research

7 years ago

Seres promotes CFO Eric Shaff to succeed Pomerantz as CEO; Exelixis' Cabometyx bags US approval for liver cancer

7 years ago

In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for ...

7 years ago

Two more big pharma vets at Roche, AstraZeneca make the leap to top biotech R&D jobs as the great migration continues

7 years ago

Cummings triggers probe into pricing practices of dozen major drugmakers

7 years ago

May the candle burn forever: Polite reminders about the JPMorgan confab

7 years ago

Merck highlights crucial hit for Keytruda in second-line esophageal carcinoma — but there are also 2 misses

7 years ago

Aimmune says US government shutdown stymied its peanut allergy drug application

7 years ago

Scoop: Pfizer once again takes out the budget ax, lopping off 150 R&D staffers and 5 preclinical biosimilar drugs

7 years ago

EMA to lose 25% of staff as hard Brexit approaches

7 years ago

FDA offers Pfizer priority review for tafamidis; Clarivate to merge with Churchill Capital

7 years ago

Is JPM worth it? As the buzzy conference dies down, debate on its value rumbles on

7 years ago

FDA staff largely unfazed by CV signal in Amgen osteoporosis drug trials

7 years ago

Buzz: This little biotech has so much going against it, somebody is going to want to buy it. Right?

7 years ago

CMO Sean Bohen joins exodus at AstraZeneca during a major R&D leadership overhaul

7 years ago

First page Previous page 982 983 984985986 987 988 Next page Last page